Months after a man died in a botched clinical trial in France, the company that ran it has opened a big research facility in New Jersey, where as many as 50 clinical trials could be done each year.
About 27 percent of Food and Drug Administration reviewers who approved hematology-oncology drugs from 2001 through 2010 left to work for the industry they previously regulated, an analysis found.
The Food and Drug Administration approved a muscular dystrophy drug despite deeply flawed evidence. Was the decision a dangerous precedent or flexible pragmatism reflecting patients' values?
Researchers analyzing recent drug spending in the U.S. say that high-priced drugs for rare diseases aren't having a widespread or significant effect on overall health care spending.
Four years after user fees were imposed to speed up the review of generic drug applications by the Food and Drug Administration, more than 4,000 generics remain in limbo.
Researchers have failed repeatedly in their efforts to slow or halt Alzheimer's disease. But there are hints that an experimental drug can do what previous medicines could not.
Mylan's move comes amid pressure from consumers and Congress to lower the allergy drug's price. In less than 10 years, the price has risen from about $100 to more than $600 for an injector two-pack.
Hundreds of pharmaceutical and medical device firms have paid doctors for their services even after the doctors were disciplined for serious misconduct by state medical boards, an analysis finds.
Researchers found that in states with medical marijuana laws on the books, the number of prescriptions dropped for drugs to treat anxiety, depression, nausea, pain, seizures and sleep disorders.